Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has launched PROIBS®, a new product aimed at treating symptoms of Irritable Bowel Syndrome (IBS) in the Australian market. This launch is strategically timed for the festive season when IBS symptoms are more prevalent. PROIBS® is a certified medical device containing AVH200®, derived from Aloe barbadensis, and is designed for long-term use without known medication interactions. The product has shown promising results in a usability study, with a high percentage of users reporting improvements. This addition to Immuron’s product line, which includes the successful Travelan® brand, is expected to strengthen its position in the digestive health market, which is projected to grow in Australia.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that focuses on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Average Trading Volume: 185,656
Technical Sentiment Signal: Hold
Current Market Cap: A$22.63M
See more data about IMC stock on TipRanks’ Stock Analysis page.